FOXO Technologies Seeks Voting Control of Ludwig Enterprises with 74.9% Stake
FOXO Technologies Inc. may gain voting control of Ludwig Enterprises Inc. (LUDG) through a 74.9% stake, pending preferred-stock purchases and voting agreements. FOXO aims to elect directors and influence decisions, with potential CEO and platform support. Deals depend on FOXO's Nasdaq listing and financing. FOXO operates in healthcare services and technology, controlled by Rennova Health Inc.
How this was made
The 30-second read
Why it matters
If the deals close, FOXO’s claimed voting power would allow it to elect or remove directors and approve or block matters submitted to LUDG stockholders, potentially reshaping governance and strategic direction.
Market read
This is a pre-closing control attempt disclosed via Schedule 13D, which can reprice governance expectations and increase event-driven trading in LUDG.
What to watch
Key overhangs are whether the preferred shares’ voting power is enforceable as described, the likelihood of director and interim CEO appointments, and what transactions FOXO may pursue if it gains control.
Background
FOXO says it entered preferred-stock purchase agreements and separate voting agreements to obtain voting control of Ludwig Enterprises, filing Schedule 13D on Oct. 29, 2026.
Ticker impact
FOXO filed a Schedule 13D claiming it may beneficially own 74.9% of LUDG and seeks voting control via preferred-stock purchase and voting agreements.
Likely volatility as markets price the probability of closing, director changes, and any subsequent consolidation or transactions.
The filing describes intent and voting arrangements before closing, but purchases are not closed and depend on conditions like FOXO’s Nasdaq listing and financing.
Market effects
Healthcare services and life-science services names may see incremental attention to governance-driven consolidation narratives, but no direct sector-wide policy or product signal is provided.
No clear regional macro linkage; impact is primarily company-specific governance and potential corporate-structure changes.
Limited global relevance because the disclosure is a US Schedule 13D and the described actions are company-level control arrangements.
Counterpoint
The voting control is conditional and the purchases have not closed, so the market may over-discount a control outcome that could fail due to financing or listing conditions.
Key entities
- acquirer/controlling bidderFOXO Technologies Inc.
Healthcare services and technology company that filed Schedule 13D seeking voting control of Ludwig Enterprises via preferred-stock purchase and voting agreements.
- targetLudwig Enterprises, Inc.
Company for which FOXO seeks voting control; purchases are not closed and depend on conditions.
- directorMark White
FOXO director mentioned as potentially invited to serve as a LUDG director and interim CEO, though no appointment has occurred.
- controllerRennova Health Inc.
Company stated to control FOXO, with CEO Seamus Lagan serving as CEO of both FOXO and Rennova.
